报价延迟最少15分钟:2025/11/16 08:41 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.66 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.00/-2.81
|
|
企业价值
13.45M
|
| 资产负债 |
|
每股账面净值
1.87
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 08:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions. |
